Complement C5
-
Subject Areas on Research
- Activation of the respiratory burst enzyme in human polymorphonuclear leukocytes by chemoattractants and other soluble stimuli. Evidence that the same oxidase is activated by different transductional mechanisms.
- Alterations of new methylated phospholipid synthesis in the plasma membranes of macrophages exposed to chemoattractants.
- Behçet's disease patients present high levels of deglycosylated anti-lipoteichoic acid IgG and high IL-8 production after lipoteichoic acid stimulation.
- Cellular serine proteinase induces chemotaxis by complement activation.
- Chemoattractant receptors on phagocytic cells.
- Component deficiencies. 5. The fifth component.
- Deficiency of the fifth component of complement in human subjects. Clinical, genetic and immunologic studies in a large kindred.
- Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
- Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview.
- Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
- Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.
- Generation of a fibroblast chemotactic factor in serum by activation of complement.
- High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients.
- Inhaled asbestos activates a complement-dependent chemoattractant for macrophages.
- Inherited human complement C5 deficiency. Nonsense mutations in exons 1 (Gln1 to Stop) and 36 (Arg1458 to Stop) and compound heterozygosity in three African-American families.
- Leukocyte chemoattractant receptors.
- Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
- Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity.
- Novel delivery of oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy model.
- Pathogenicity of Saccharomyces cerevisiae in complement factor five-deficient mice.
- Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
- Potential pathogenicity of deglycosylated IgG cross reactive with streptokinase and fibronectin in the serum of patients with rheumatoid arthritis.
- Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
- Role of complement activation in obliterative bronchiolitis post-lung transplantation.
- Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia.
- Substance P primes human neutrophil activation: a mechanism for neurological regulation of inflammation.
- Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
- Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts.